| ABSTRACT Objective: To study the effect and safety of using monosialoganglioside for adjunctive therapy in acute craniocerebral injury treatment. Methods: 284 patients with acute craniocerebral injury in our hospital were selected and randomly divided into control group(142 cases) and observation group(142 cases). Both groups received the routine combined treatment, while the observation group also continued to take monosialoganglioside 40 mg·d-1 at the meantime. Treatment was 3 weeks for both groups. The GCS score, neural function defect scale, Barthel index rating scale, and the change of blood pressure, heart rate, intracranial pressure, cerebral hematoma volume of two groups were obseved before and after treatment. The curative effect and adverse drug reactions were also campared. Results:After the treatment, the incidence of abnormal heart rate changes and blood pressure in the observation group were significantly lower than that in the control group（P<0.05）, the intracranial pressure in the observation group was better than that in the control group（P<0.05）. The GCS, the neural function defect scale and the Barthel index score after treatment was improved (P<0.05). And the indicators in observation group were significantly higher than that in control group respectively, with statistical difference（P<0.05）. The volume of brain hematoma was significantly decreased（P<0.05）, and the volume of brain hematoma in observation group was significantly less than that in control group respectively, with statistical difference（P<0.05）. The total efficacy rates of the observation group was 83.80%, which was higher that in the control group（P<0.05）. The incidence of adverse drug reactions between the two groups had no statistical significance（P>0.05）. Conclusion:For patients with acute craniocerebral injury, monosialoganglioside used on the basis of conventional treatment could significantly improve neurological function in patients, reduced the intracranial pressure, and improve treatment efficiency. |
